ACC: Empagliflozin Does Not Cut Risk for Heart Failure After Acute MI
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 10, 2024 -- Empagliflozin does not reduce the risk for first hospitalization for heart failure or death among patients at increased risk for heart failure after acute myocardial infarction, according to a study published online April 6 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta.
Javed Butler, M.D., M.P.H., from the Baylor Scott and White Research Institute in Dallas, and colleagues randomly assigned patients hospitalized for acute myocardial infarction who were at risk for heart failure to empagliflozin 10 mg daily or placebo in addition to standard care within 14 days after admission (3,260 and 3,262 patients, respectively).
The researchers found that a first hospitalization for heart failure or death from any cause occurred in 8.2 and 9.1 percent of patients in the empagliflozin and placebo groups, respectively, during a median follow-up of 17.9 months (incidence rates, 5.9 and 6.6 events, respectively, per 100 patient-years; hazard ratio, 0.90; 95 percent confidence interval, 0.76 to 1.06; P = 0.21). A first hospitalization for heart failure occurred in 3.6 and 4.7 percent of patients in the empagliflozin and placebo groups, respectively (hazard ratio, 0.77; 95 percent confidence interval, 0.60 to 0.98), and death from any cause occurred in 5.2 and 5.5 percent, respectively (hazard ratio, 0.96; 95 percent confidence interval, 0.78 to 1.19). Adverse events were consistent with the known safety profile for empagliflozin.
"Empagliflozin did not reduce the risk of the composite primary end point event -- a first hospitalization for heart failure or death from any cause -- in patients with acute myocardial infarction who were at increased risk for heart failure," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Boehringer Ingelheim and Eli Lilly, which manufacture empagliflozin and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Gains in Heart Failure Mortality Have Been Erased
FRIDAY, April 26, 2024 -- Declines in heart failure-related mortality from 1999 to 2012 were entirely reversed from 2012 to 2021, according to a research letter published online...
Reports of Injuries, Deaths Prompt FDA to Recall Heart Failure Devices
WEDNESDAY, April 17, 2024 -- The HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories, are now under a strict U.S. Food and Drug...
American College of Cardiology, April 6 to 8
The annual meeting of the American College of Cardiology was held from April 6 to 8 in Atlanta and attracted more than 12,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.